News and Media Coverage

New Delhi: Amid the raging coronavirus pandemic, PNB Vesper Life Science Private Limited on Friday received approval from the Drug Controller General of India to conduct the clinical trial of their drug on Covid-19 patients. Speaking to IANS about the … Continued

Leading Indian pharma research company PNB Vesper Life science has received approval from the Drug Controller General of India (DCGI) to conduct phase-2b clinical trial of its propriety drug PNB-001 (GPP-Baladol) for testing in Covid-19 patients. PN Balaram, CEO of … Continued

PNB Vesper, a Kochi-based life sciences company, on September 11 said it has received approval from the Drugs Controller General of India (DCGI) to conduct the Phase 2b clinical trial of their propriety drug PNB-001 (GPP-Baladol) on COVID-19 patients. The … Continued

The Indian Pharma Research company claimed that if their propriety drug PNB-001 – Baladol – works successfully in Covid-19 patients, it would be the “first new chemical entity in the world for treatment of the disease”. The drug has shown … Continued

City-based pharma research firm PNB Vesper has secured the drug controller’s permission to launch phase-II clinical trials for a potential COVID-19 drug — making it the first in the world to begin such trials for a new chemical entity, a … Continued